The following is a contributed article from Essity, shared by Pharmx as part of our ongoing Supplier Spotlight series.

Antimicrobial resistance (AMR) continues to challenge healthcare systems worldwide, affecting patient outcomes, increasing hospital stays, and placing pressure on antimicrobial stewardship (AMS) efforts. For pharmacists and healthcare professionals, the focus is shifting from simply treating infections to preventing them, using approaches that minimise the risk of resistance development. Infections remain a significant challenge, despite well-established prevention strategies, including antibiotic prophylaxis and aseptic techniques, these infections persist. This underscores the need for additional interventions that align with antimicrobial stewardship (AMS) principles, particularly those that reduce microbial burden without relying on antimicrobial agents. 

Leukomed® Sorbact® represents one such innovation. Unlike traditional antimicrobial dressings that depend on chemical agents such as silver or iodine, Sorbact® Technology works through a physical mode of action. Its hydrophobic surface binds bacteria and fungi, removing them from the wound when the dressing is changed. Importantly, because this mechanism is physical rather than chemical, it does not exert selective pressure on microorganisms, meaning antimicrobial resistance is not expected. 

This unique mode of action is especially relevant for pharmacists, who play a critical role in promoting responsible antimicrobial use. Incorporating non-antimicrobial technologies into wound management strategies supports broader AMS goals by reducing reliance on antibiotics and limiting unnecessary exposure to antimicrobial agents. 

From a clinical perspective, the use of Leukomed® Sorbact® can contribute to infection prevention by managing microbial load at the wound surface. When used as part of a comprehensive infection prevention strategy, it complements protocols rather than replacing them. This aligns with the “Start Smart” principle, choosing interventions early in the care pathway that optimise outcomes while minimising unintended consequences. 

For pharmacy professionals, understanding the role of such technologies within AMS pathways is increasingly important. Decision-making is no longer limited to medication selection; it extends to recommending and supporting products that align with stewardship objectives. Sorbact® provides an opportunity to influence outcomes upstream, before infection develops or escalates. 

However, adoption of non-antimicrobial solutions requires a shift in mindset. Traditional assumptions often equate antimicrobial activity with efficacy. Yet, in the context of rising resistance, alternative mechanisms should be recognised as both clinically valuable and strategically important. Physical bacterial binding offers a targeted, resistance-neutral approach that fits well within modern infection prevention frameworks. 

Leukomed® Sorbact® reflects a broader evolution in healthcare, one that prioritises prevention, sustainability and responsible antimicrobial use. For pharmacists, integrating such options into practice supports both individual patient care and the global effort to combat AMR, while aligning closely with the direction of current AMS guidelines. 

A session on antimicrobial stewardship will be covered at this years PSA 26 Conference in NSW on Saturday August 1st . Come and see Essity at Booth 37.